Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

TNF Pharmaceuticals Inc TNFA

Healthcare
TNF Pharmaceuticals, Inc., formerly MyMD Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company focused on developing novel therapies for age-related diseases and autoimmune and inflammatory conditions. It is focused on developing and commercializing two therapeutic platforms based on well-defined therapeutic targets: MYMD-1 and Supera-CBD. MYMD-1 is a drug platform based on a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to treat diseases and disorders marked by acute or chronic inflammation. Supera-CBD is being developed to treat chronic pain, addiction and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve upon the growing CBD market, which includes both Food and Drug Administration (FDA) approved drugs and CBD products not currently regulated as drugs.


NDAQ:TNFA - Post by User

TNF Pharmaceuticals Inc
<< Previous
 Bullboard Posts
User Avatar Image
(228)
•••
Post by whytestockson May 21, 2024 8:00pm
99 Views
Post# 36051022

MyMD Pharmaceuticals Secures Strategic Investments

MyMD Pharmaceuticals Secures Strategic Investments
JUST IN: $MYMD MyMD Pharmaceuticals Secures Strategic InvestmentsUp to $42 Million in Two-Part Funding from New Strategic Investor and Existing Shareholders with Committed Closing of an Aggregate of $14 Million Up Front MyMD Pharmaceuticals, Inc.&#xAE; (Nasdaq: MYMD) (&#x201C;MyMD&#x201D; or &#x201C;the Company&#x201D;), a clinical stage biopharmac...MYMD - MyMD Pharmaceuticals Secures Strategic Investments

<< Previous
 Bullboard Posts
Dealroom for high-potential pre-IPO opportunities